Vimian Group ABCHIX:VIMIAS 59 Market Cap is kr15,814 Mil as of Jul. 09, 2026. GuruFocus rates CHIX:VIMIAS with a GF Score™ of 59/100 and a GF Value™ of kr31.92 (Fairly Valued). The stock has 2 warning signs investors should review. Among 218 Medical Diagnostics & Research companies, Vimian Group AB ranks better than 81.19% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Vimian Group AB's share price for the quarter that ended in Mar. 2026 was kr25.6. Vimian Group AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 529 Mil. Therefore, Vimian Group AB's market cap for the quarter that ended in Mar. 2026 was kr13,549 Mil.
Vimian Group AB's quarterly market cap
declined
from Sep. 2025 (kr21,139 Mil) to Dec. 2025 (kr15,275 Mil) and
declined
from Dec. 2025 (kr15,275 Mil) to Mar. 2026 (kr13,549 Mil).
Vimian Group AB's annual market cap
stayed the same
from Dec. 2023 (kr0 Mil) to Dec. 2024 (kr0 Mil) but then
increased
from Dec. 2024 (kr0 Mil) to Dec. 2025 (kr15,275 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Vimian Group AB's Enterprise Value for Today is kr18,119 Mil.
Vimian Group AB (CHIX:VIMIAs) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Vimian Group AB Market Cap Related Terms
Vimian Group AB Market Cap Historical Data
* Premium members only.
The historical data trend for Vimian Group AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:VIMIAS vs TMO, DHR, IDXX: Market Cap Comparison
For the Diagnostics & Research subindustry, Vimian Group AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Vimian Group AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB (CHIX:VIMIAS) has a Market Cap of kr15,814 Mil as of Jul. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vimian Group AB and its competitors. According to the industry distribution chart, Vimian Group AB ranks #41 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 18.8%.
Is Vimian Group AB's Market Cap too high?
Vimian Group AB's current Market Cap is kr15,814 Mil. Based on the distribution chart, Vimian Group AB ranks #41 out of 218 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Vimian Group AB has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #41 out of 218 companies for Market Cap. This places Vimian Group AB in the top 19% of its industry — outperforming the majority of peers. The industry median Market Cap is 58.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 58.64, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vimian Group AB and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 58.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimian Group AB's current Market Cap is kr15,814 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Based on GuruFocus' analysis, Vimian Group AB (CHIX:VIMIAS) is currently considered Fairly Valued. The stock's GF Value™ is kr31.92, compared to a current price of kr30.28 — trading 5.2% below its estimated fair value. The current Market Cap is kr15,814 Mil. Vimian Group AB's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Vimian Group AB (CHIX:VIMIAS), the current Market Cap is kr15,814 Mil as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (CHIX:VIMIAS) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of kr30.28 is trading 5.2% below its estimated GF Value™ of kr31.92.
GuruFocus considers Vimian Group AB to be Fairly Valued.
Key valuation signals for CHIX:VIMIAS:
Market Cap: kr15,814 Mil
GF Value™: kr31.92 vs. price of kr30.28 (5.2% below fair value)
No single metric tells the full story. See the CHIX:VIMIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
59GF Score
Get the complete analysis for CHIX:VIMIAS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VIMIAS has been successfully added to your 
